Yvanka Gilliam, CEO of Clinical Research Advancement, is a recognized leader driving innovation in molecular diagnostics and precision oncology. With 25+ years of experience, she collaborates with companies to leverage cutting-edge technologies and data-driven insights to improve patient outcomes and generate valuable real-world evidence.
Clinical Research Advancement, with offices in Singapore, Dubai, and the United States, accelerates oncology compound launches across the US, APAC, MEA and LATAM regions. Previously, Yvanka held key leadership roles at CRIS, Diaceutics, Kantar Health, and IQVIA, shaping clinical research and market access strategies. She holds a PharmD from the University of Michigan and an MBA in International Business from Rutgers University.